A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Potassium cation
Ethylmorphine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ethylmorphine.
Potassium cation
Fencamfamin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Fencamfamin.
Potassium cation
Diamorphine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Diamorphine.
Potassium cation
Dihydroetorphine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Dihydroetorphine.
Potassium cation
Bufotenine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Bufotenine.
Potassium cation
MMDA
The risk or severity of adverse effects can be increased when Cannabidiol is combined with MMDA.
Potassium cation
Glutethimide
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Glutethimide.
Potassium cation
Methadyl acetate
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Methadyl acetate.
Potassium cation
Yohimbine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Yohimbine.
Potassium cation
Rasagiline
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Rasagiline.
Potassium cation
Penbutolol
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Penbutolol.
Potassium cation
Lithium cation
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Lithium cation.
Potassium cation
Hexobarbital
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Hexobarbital.
Potassium cation
Heptabarbital
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Heptabarbital.
Potassium cation
Butobarbital
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Butobarbital.
Potassium cation
Aprobarbital
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Aprobarbital.
Potassium cation
Amobarbital
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Amobarbital.
Potassium cation
Taranabant
The risk or severity of adverse effects can be increased when Taranabant is combined with Cannabidiol.
Potassium cation
Rimonabant
The risk or severity of adverse effects can be increased when Rimonabant is combined with Cannabidiol.
Potassium cation
SLV319
The risk or severity of adverse effects can be increased when SLV319 is combined with Cannabidiol.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3